KINLOCK, Ballington*; SUN, Jingxia ; SUN, Yujie ; TAN, Kim ; Medgar Evers College; Nanjing Medical University; Nanjing Medical University; Winston-Salem State University: Treatment Of Md-mb 435 Cancer Cell Line With Troglitazone And Epirubicin Hydrochloride Synergistically Inhibits Proliferation And Induces Apoptosis

Troglitazone (TRO), a Peroxisome Proliferator- activated receptor gamma (PPARy) ligand, was widely used in the United States in the treatment of type 2 diabetes. Recent studies have shown that PPAR gamma activation by TRO inhibited cancer cell proliferation. In addition, studies have shown that PPAR gamma is suppressed at significant levels in human primary breast cancer. In our study we wanted to see if TRO and Epirubicin Hydro Chloride (a widely used tumor suppressant drug) had a synergistic effect when used together in the treatment of breast cancer cells. We used different concentrations of TRO on the MD-MB 435 cancer cell line to find the concentration that have the best inhibitory effect. Utilization of MTT (3-[4,5-dimethylthiazol-2,5-diphenyl tetrazolium bromide) assay showed that a concentration of 10 micro molar of TRO had the best inhibitory effect. We then treated the same cell line with Epirubicin Hydro Chloride along with 10 micro molar TRO to see if the use of these two chemicals would carry out there individual effects on the cells thus creating an effect that is more effective in the cancer cell growth regulation. Through flow-cytometry analysis, we found that this combination of drugs had a synergistic effect and with further study this may offer a new way for breast cancer therapy.